Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement rejections under 35 U.S.C. §112(a). The USPTO routinely rejects claims as too broad. The heightened disclosure requirements increase laboratory costs to generate sufficient data for a §112(a)-proof specification.
Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement rejections under 35 U.S.C. §112(a). The USPTO routinely rejects claims as too broad. The heightened disclosure requirements increase laboratory costs to generate sufficient data for a §112(a)-proof specification.
